Checkpoint Therapeutics jumps after deal to be acquired by Sun Pharma
Written by Emily J. Thompson, Senior Investment Analyst
Checkpoint Therapeutics Acquisition: Checkpoint Therapeutics' shares surged 64% to $4.06 following the announcement of its acquisition by Sun Pharmaceutical Industries, which will pay $4.10 per share and offer potential additional payments based on regulatory approvals for cosibelimab.
Transaction Details: The deal includes a royalty agreement with Fortress Biotech, Checkpoint's controlling stockholder, and is expected to close in the second quarter of 2025, pending regulatory approvals and shareholder consent.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
